## IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A process for producing solid dosage forms, in which a moldable composition which comprises

- a) 50 to 99.4% by weight of at least one crosslinked nonthermoplastic carrier,
- b) 0.5 to 30% by weight of at least one adjuvant selected from the group consisting of thermoplastic polymers, lipids, sugar alcohols, sugar alcohol derivatives and solubilizers and
- c) 0.1 to 49.5% by weight of at least one active ingredient, is formed at a temperature at or above the softening point of the adjuvant, but at least 70°C, and subsequently cooled.

Claim 2 (Original): The process according to claim 1, where the composition comprises

- a) 50 to 90% by weight of at least one crosslinked nonthermoplastic carrier,
- bl) 5 to 30% by weight of at least one thermoplastic polymer,
- b2) 0.5 to 20% by weight of at least one solubilizer,
- c) 0.1 to 45.5% by weight of at least one active ingredient.

Claim 3 (Currently Amended): The process according to claim 1-or 2, where the crosslinked nonthermoplastic carrier is selected from the group consisting of crosslinked polyvinylpyrrolidone, and crosslinked sodium carboxymethylcellulose and mixtures thereof.

Claim 4 (Currently Amended): The process according to any of the preceding claims claim 1, where the thermoplastic polymer is a homo- or copolymer of vinylpyrrolidone.

Claim 5 (Currently Amended): The process according to any of the preceding claims claim 1, where the sugar alcohol is selected from the group consisting of sorbitol, xylitol, mannitol, maltitol, and the sugar alcohol derivative isomalt and mixtures thereof.

Claim 6 (Currently Amended): The process according to any of the preceding claims claim 1, where the lipid is selected from the group consisting of fatty acids, fatty alcohols, fats, waxes, mono- and diglycerides, and phosphatides and mixtures thereof.

Claim 7 (Currently Amended): The process according to any of the preceding claims claim 1, where the solubilizer is selected from the group consisting of sorbitan fatty acid esters, polyalkoxylated fatty acid esters, and polyalkoxylated ethers of fatty alcohols and mixtures thereof.

Claim 8 (Currently Amended): The process according to any of the preceding claims claim 1, where the active ingredient has a solubility in water at 25°C of less than 1 mg/ml.

Claim 9 (Currently Amended): The process according to any of the preceding claims claim 1, where the cooled composition is comminuted and compressed to the dosage form.